The predominance of MED18 in exerting oncogenic activity of SNHG3 was validated by the rescue assay as well, wherein co-knockdown of MED18 significantly reversed the tumor suppressing function elicited by SNHG3-silencing. This evidence concerns the gene SNHG3 and neoplasm.